CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues:
Premiums earned, net (Net of ceded premiums of $101 and $122 for the three months ended March 31, 2024 and 2023, respectively)	$ 341,722	$ 317,086
Other income	5,200	4,906
Total revenues	346,922	321,992
Operating expenses:
Net medical claims incurred	265,162	274,789
Salaries and benefits	59,223	68,981
General and administrative expenses	44,569	57,644
Premium deficiency reserve benefit	0	(1,810)
Depreciation and amortization	318	279
Restructuring costs	353	1,807
Total operating expenses	369,625	401,690
Loss from continuing operations	(22,703)	(79,698)
Loss on investment	467	0
Net loss from continuing operations	(23,170)	(79,698)
Net income from discontinued operations (Note 17)	4,000	7,092
Net loss	$ (19,170)	$ (72,606)
Continuing Operations:
Basic weighted average number of Class A and Class B common shares and common share equivalents outstanding (in shares)	486,374,644	478,805,067
Diluted weighted average number of Class A and Class B common shares and common share equivalents outstanding (in shares)	486,374,644	478,805,067
Basic net loss per share (in dollars per share)	$ (0.05)	$ (0.17)
Diluted net loss per share (in dollars per share)	$ (0.05)	$ (0.17)
Discontinued operations:
Basic weighted average number of Class A and Class B common shares and common share equivalents outstanding (in shares)	486,374,644	478,805,067
Diluted weighted average number of Class A and Class B common shares and common share equivalents outstanding (in shares)	567,451,166	566,629,082
Basic earnings per share (in dollars per share)	$ 0.01	$ 0.01
Diluted earnings per share (in dollars per share)	$ 0.01	$ 0.01
Net unrealized (loss) gain on available-for-sale investments	$ (190)	$ 2,343
Comprehensive loss	$ (19,360)	$ (70,263)